(2S)-2-amino-6-[(carboxymethyl)amino]hexanoic acid, 98.0%, 25mg

4-amino-3-(pyridin-3-yl)butanoic acid, 95.0%, 250mg

2-(1-Naphthyl)acetamide>97.0%(GC)500g

(2S,4R)-1-(tert-Butoxycarbonyl)-4-hydroxypiperidine-2-carboxylic acid, 95.0%, 5g

5-Bromo-4-chloro-2-fluoropyridine, 97%, 5g

5-Methyl-3-(methylsulfanyl)-1,2,4-triazine, 95+%, 10g

2-(hydroxymethyl)-N-methylbenzamide, 95.0%, 500mg

2,4,6-Tri-tert-butylpyrimidine, 95.0%, 10g

rel-(1R,2S)-2-Aminocyclopentanecarboxamide hydrochloride, 97.0%, 1g

3,3-Difluorocyclobutanamine hydrochloride, 95.0%, 25g

Oxalic acid diethyl ester, >=99%, for synthesis, 1 l, plastic packaging.

GC capillary column ROTI®Cap-1701, 25 m, 0.32 mm, 0.25 µm, 1 Piece(s)

(R)-3-Amino-3-(thiophen-3-yl)propanoic acid, 95%, 250mg